Business Wire

LifeArc and GVK BIO Celebrate a Decade of Partnership, Transforming Research into Life-Saving Medicines

Share

GVK BIO, a leading global Contract Research and Development Organisation (CRDO), and LifeArc, one of UK’s top medical research charities, are pleased to announce the 10th anniversary of a successful partnership. The collaboration between LifeArc and GVK BIO brings together two organizations with a singular vision: advancing novel research ideas into potential medicines that can make a significant difference to patients.

LifeArc’s novel approach involves levering partnerships with academia and leading service organizations to advance discoveries into promising medicines. Over the past decade, LifeArc scientific teams have focused their efforts on modulating novel targets with therapeutic potential in diseases where there is patient need, with the GVK BIO team assisting in synthesizing complex molecules rapidly and cost effectively to drive iterative improvement in efficacy and safety.

Promising novel chemical entities discovered from this partnership have been either advanced by LifeArc into clinical development, or have been licensed out to leading global pharmaceutical companies, including a recently announced deal in neuroscience. As the partnership evolved from a tactical relationship into a preferred partnership, the GVK BIO team has augmented LifeArc’s internal biology efforts, by supporting biochemical assays, carrying out drug metabolism and pharmacokinetics profiling studies, and soon, will be developing cell-based assays and running protein expression and purification studies.

“It has been our privilege to have collaborated with LifeArc and its world class team of scientists that have delivered medicines such as Keytruda®, Tysabri®, and Entyvio® among others,” said Manni Kantipudi, Director & Chief Executive Officer, GVK BIO. “The longevity of this partnership, and the transformative results of the collaboration, serve as a testament to the capabilities of the GVK BIO team and its commitment to work with customers to make a difference in human life. We look forward to continuing this successful relationship with LifeArc in the coming years.”

Commenting on the partnership, Melanie Lee, Chief Executive Officer, LifeArc, said, “At LifeArc, we’re committed to translating scientific innovation to benefit patients. Our partnership with GVK BIO is a strong example of how shared goals and collaboration can create real value.”

About GVK BIO

GVK BIO, a leading Contract Research & Development Organization servicing the global Biopharma industry; is headquartered in Hyderabad, India with operations in five sites including California, USA. Established in 2001, GVK BIO has over 18 years of experience across the Research and Development value chain with a focus on speed and quality while ensuring safety and compliance. GVK BIO’s team of over 2100 highly qualified scientists, backed by a no-conflict business model, well-defined and scalable processes, modern facilities, and a strong customer-centric partnering approach, focus on bringing its customers’ products to market. www.gvkbio.com

About LifeArc

LifeArc is a self-funded medical research charity. Our mission is to advance translation of early science into health care treatments or diagnostics that can be taken through to full development and made available to patients. We’ve been doing this for more than 25 years and our work has resulted in four licensed medicines and a diagnostic for antibiotic resistance. Our success allows us to explore new approaches to stimulate and fund translation. We have our own drug discovery and diagnostics facilities, supported by experts in technology transfer and intellectual property who also provide services to external clients. Our model is built on collaboration, and we partner with a broad range of groups including medical research charities, research organisations, industry and scientists. www.lifearc.org ; Twitter @lifearc1

Contact information

Dorothy Paul
Dorothy.paul@gvkbio.com
+91 9908130236

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EURid Launches New Eligibility Criteria19.10.2019 04:30:00 CESTPress release

The top-level internet domain .eu is the eighth largest country code extension on the internet and, as of October 2019, we have more than 3.6 million registrations spread out across Europe. Since its launch in 2006, only companies and individuals residing within the EU and EEA member states have been eligible to register the .eu domain name. However, striving to meet the needs of an ever-changing digital environment, the eligibility criteria for the registration of .eu domain name has now been extended to all EU citizens living around the world. With millions of Europeans living around the world – our hope is to provide these individuals, living far from their native lands, with a personal online platform through which they can share their stories with families and friends back home. “We are excited to be able to extend the registration criteria to EU citizens around the world. The .eu domain is now closer to your ambitions, achievements and dreams. It is the bridge connecting you to y

ams to Launch New Takeover Offer for OSRAM at EUR 41.00 Per Share With Minimum Acceptance Threshold of 55%18.10.2019 17:16:00 CESTPress release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION ams (SIX: AMS), a leading worldwide supplier of high performance sensor solutions, announces that it intends to launch a new all-cash takeover offer for OSRAM Licht AG ("OSRAM") for 100% of the share capital of OSRAM at a price of EUR 41.00 per share ("Offer"). The Offer which represents a premium of 42% to the undisturbed OSRAM share price of EUR 28.92 as of 2 July 2019 will be launched by ams Offer GmbH, a newly incorporated, wholly owned subsidiary of ams. ams is the largest shareholder in OSRAM with a direct shareholding of 19.99% which ams will not exceed outside of the Offer. As a result of ams' shareholder position, ams has lowered the minimum acceptance threshold to 55%. Winning way forward for ams and OSRAM The combination of ams and OSRAM allows ams to create a global leader in sensor solutio

Resecurity Appoints Selene Giupponi Managing Director of Resecurity Europe18.10.2019 15:38:00 CESTPress release

Resecurity, a cybersecurity company that delivers in-depth analysis layered on top of the most comprehensive, exclusive sets of data from the Deep and Dark Web, announces that Selene Giupponi has joined as Managing Director and will be based in Italy. A digital forensics expert, Selene adds significant value to Resecurity’s operations in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191018005415/en/ Resecurity Appoints Selene Giupponi Managing Director of Resecurity Europe (Photo: Business Wire) Selene has extensive expertise in digital forensics and is often called as an expert witness regarding digital and mobile forensics on domestic and international cases, investigations and court trials. She is a specialized IT trainer in Italy and teaches digital, mobile, cloud and mainframe forensics, cybercrime and information security at various Italian universities. “Selene brings a depth of experience to our team and we

Secure-24 Completes Acquisition of Symmetry Corporation18.10.2019 14:20:00 CESTPress release

NTT Ltd., the newly formed, world-leading global technology services provider, and Symmetry Holding Inc. (Symmetry), a U.S.-based leading provider of SAP managed services, today announced that Secure-24 Intermediate Holdings, Inc. (Secure-24), part of the Managed Services division of NTT Ltd., has completed the acquisition of Symmetry Corporation effective October 17, 2019. “The powerful business combination of Secure-24 and Symmetry leverages the strengths of both companies around Secure-24’s foundation of delivering managed IT operations, application hosting and cloud services to enterprises worldwide,” said Mike BeDell, Chief Executive Officer, Secure-24. “As we begin to integrate Symmetry’s portfolio into Secure-24’s portfolio, through a shared vision, we look forward to providing even greater value that accelerates our clients’ business success.” Symmetry, headquartered in Brookfield, Wisconsin, will expand the scale of SAP managed services capabilities of Secure-24 and bring new

New Research Reveals Updated Patient Preferences on Digital Health Technology18.10.2019 13:00:00 CESTPress release

ResMed (NYSE: RMD, ASX: RMD) today announced results from a company-led survey, revealing new patient preferences on digital health technology. The survey highlights a reason for optimism that the markets for digital health technology will only continue to grow. The survey of a nationally representative sample of 3,000 Americans, conducted in partnership with Edelman Intelligence, revealed that the use of – and confidence in – remote digital health technology is widespread: 56% of those surveyed currently monitor their health with at least one digital data collection tool. Also, 60% of people attempt to diagnose themselves after browsing symptoms on the Internet – including 76% of Millennials. Perhaps more surprising, remote digital health technology seems to have deepened people’s connection with their physicians rather than distanced them from one another. Over half of those surveyed agree that technology has improved their relationship with their primary care provider, and many woul

CHMP Grants Positive Opinion for Expanded Use of Janssen’s Darzalex®▼(daratumumab) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible18.10.2019 12:43:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended broadening the existing marketing authorisation for Darzalex® (daratumumab) to include the use of daratumumab in combination with lenalidomide and dexamethasone (DRd) for patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT). “As multiple myeloma can become more complex with each relapse, it is important that patients receive the latest treatment options with the goal of extending their first remission period,” said Professor Thierry Facon, M.D., Service des Maladies du Sang, Hôpital Claude Huriez, Lille, France, and principal investigator of the MAIA study. “For newly diagnosed patients who are transplant ineligible, this regimen could be an important frontline therapy option and reinforces the consistent clinical profile of daratumuma